A critical appraisal of the selegiline transdermal system for major depressive disorder.
BACKGROUND Concurrent use of monoamine oxidase inhibitors (MAOIs) during a course of electroconvulsive therapy (ECT) is controversial. OBJECTIVE In this report, the authors present outcomes of this concurrent treatment approach. METHOD The authors present two cases of patients taking the newest MAOI approved for depression, namely, transdermal selegiline, while receiving ECT. RESULTS The authors conclude that there is no evidence of complications or adverse events associated with concurrent use of ECT and low-dose transdermally administered selegiline. CONCLUSION The authors further conclude that beginning a low dose of transdermal selegiline before finishing a course of ECT is a viable option for relapse prevention in the treatment of depression.